Published in Cancer Res on January 23, 2013
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Med (2013) 0.95
CD24(+) cells fuel rapid tumor growth and display high metastatic capacity. Breast Cancer Res (2015) 0.92
Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer (2013) 0.88
SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells. PLoS Genet (2014) 0.84
Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. Proc Natl Acad Sci U S A (2014) 0.82
Tumor Heterogeneity-A 'Contemporary Concept' Founded on Historical Insights and Predictions. Cancer Res (2016) 0.80
Discovery of consensus gene signature and intermodular connectivity defining self-renewal of human embryonic stem cells. Stem Cells (2014) 0.79
Optogenetic regulation of site-specific subtelomeric DNA methylation. Oncotarget (2016) 0.78
A new strategy using ALDHhigh-CD8+T cells to inhibit tumorigenesis. PLoS One (2014) 0.78
Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer (2013) 0.78
Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. Mol Cancer (2017) 0.78
Chloroquine, an autophagy inhibitor, potentiates the radiosensitivity of glioma initiating cells by inhibiting autophagy and activating apoptosis. BMC Neurol (2016) 0.76
TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget (2017) 0.75
FOXC2 augments tumor propagation and metastasis in osteosarcoma. Oncotarget (2016) 0.75
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clin Cancer Res (2015) 0.75
Cell injury, retrodifferentiation and the cancer treatment paradox. Tumour Biol (2015) 0.75
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell (2007) 5.14
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One (2009) 3.89
Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell (2008) 3.87
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med (2005) 3.06
Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med (2007) 3.05
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells (2005) 3.00
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (2011) 2.74
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells (2009) 2.68
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica (2005) 2.66
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood (2008) 2.55
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells (2010) 2.54
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood (2009) 2.41
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med (2007) 2.38
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood (2005) 2.28
CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. Eur J Immunol (2012) 2.27
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood (2004) 2.14
An antagonistic pair of FT homologs mediates the control of flowering time in sugar beet. Science (2010) 2.07
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst (2007) 2.06
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood (2002) 2.03
Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res (2007) 2.03
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther (2002) 2.03
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol (2010) 2.02
Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2008) 1.99
Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res (2009) 1.96
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood (2005) 1.93
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood (2006) 1.85
Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol (2007) 1.83
Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One (2012) 1.82
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma (2012) 1.80
Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol (2004) 1.79
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer (2004) 1.75
Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood (2012) 1.74
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther (2006) 1.74
In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci (2004) 1.73
Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood (2004) 1.70
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol (2012) 1.70
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res (2007) 1.67
CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures. Cell Stem Cell (2013) 1.65
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell (2010) 1.65
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica (2010) 1.65
Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood (2006) 1.62
Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells. Lab Chip (2009) 1.61
The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res (2007) 1.60
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med (2003) 1.60
Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells (2007) 1.59
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 1.58
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol (2003) 1.57
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 1.57
DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood (2012) 1.56
High-resolution video monitoring of hematopoietic stem cells cultured in single-cell arrays identifies new features of self-renewal. Proc Natl Acad Sci U S A (2006) 1.56
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res (2004) 1.55
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood (2006) 1.55
The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res (2008) 1.53
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest (2012) 1.53
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol (2002) 1.52
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood (2013) 1.52
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematol (2013) 1.51
Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res (2009) 1.51
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer (2003) 1.50
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther (2008) 1.49
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood (2009) 1.47
Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood (2006) 1.47